Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

Luminex Corporation7,462 enrolled

Overview

The purpose of this study is to assess the agreement of clinical performance between the proposed NeoPlex 4 assay and NeoPlex System and the comparator devices in clinical use in newborn screening programs for detection of T4, TSH, 17-OHP and IRT.

The proposed (investigational) NeoPlex4 assay measures levels of thyroxine (T4), thyrotropin (hTSH), 17-alpha-OH-progesterone (17-OHP) and immunoreactive trypsinogen (IRT) from dried blood specimens (DBS) collected from neonates to screen for congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH) and cystic fibrosis (CF). The Clinical Evaluation of the xMAP® NeoPlex4™ Assay (NeoPlex4) for Detection of T4, TSH, 17-OHP and IRT using the NeoPlex System is a multi-center method concordance study on a combination of prospectively collected neonatal dried blood spots and pre-selected archived frozen dried blood spots that have been demonstrated to be positive for 17-OHP (CAH), IRT (CF), and T4 or TSH (CH). The study will be conducted at selected sites that routinely perform newborn screening testing in the United States.

Study Type

OBSERVATIONAL

Enrollment

7,462

Conditions

Adrenal Hyperplasia, Congenital Congenital Hypothyroidism Cystic Fibrosis

Eligibility

Sex: ALLMin age: 1 DayMax age: 7 DaysHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The dried blood spot specimen was collected on an FDA-cleared collection paper that has not yet passed its expiration dating. * Prospective specimens used in this study should only be those collected for the first time from a subject, or initial collection specimens. Exclusion Criteria: * Collected within 24 hours of birth. * Specimens stored at ambient temperature for greater than 14 days prior to testing. * The specimen DBS appears diluted. * The specimen DBS shows evidence of clotting, caking, layering or serum rings. * The DBS punched disks were punched too close to the edge of the blood spot or show printed markings. * The specimen or collection card was contaminated with fecal material. * Non-eluting blood spot due to deterioration of sample caused by exposure to heat and humidity.

Locations (3)

New York State Department of Health

Albany, New York, United States

Tennessee Department of Health

Nashville, Tennessee, United States

Unified State Laboratories: Public Health

Taylorsville, Utah, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.